Nio Vs Rivian Stock, Which EV Is Best?
Nio (NYSE:NIO) and Rivian (NASDAQ:RIVN) are two EV startups that…
Sell
15
SWTX Quote, Financials, Valuation and Earnings
Last price:
$36.97
Seasonality move
:
5.59%
Day range:
$38.57 - $42.44
52-week range:
$28.21 - $62.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.13x
P/B ratio:
6.09x
Volume:
3.3M
Avg. volume:
2.2M
1-year change:
-12.2%
Market cap:
$2.9B
Revenue:
$191.6M
EPS (TTM):
-$3.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$66.9M | -$0.74 | 218.64% | -37.01% | $72.88 |
|
ACAD
ACADIA Pharmaceuticals
|
$233.6M | -$0.03 | 16.28% | -91.94% | $24.85 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.27 |
|
AXSM
Axsome Therapeutics
|
$121.2M | -$1.30 | 61.86% | -6.01% | $173.89 |
|
GRCE
Grace Therapeutics
|
-- | -$0.24 | -- | -63.24% | $11.88 |
|
INSM
Insmed
|
$91.6M | -$1.36 | 15.09% | -29.38% | $95.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$39.09 | $72.88 | $2.9B | -- | $0.00 | 0% | 15.13x |
|
ACAD
ACADIA Pharmaceuticals
|
$15.38 | $24.85 | $2.6B | 11.31x | $0.00 | 0% | 2.67x |
|
ADMA
ADMA Biologics
|
$18.01 | $25.27 | $4.3B | 21.96x | $0.00 | 0% | 10.26x |
|
AXSM
Axsome Therapeutics
|
$98.86 | $173.89 | $4.8B | -- | $0.00 | 0% | 12.28x |
|
GRCE
Grace Therapeutics
|
$2.00 | $11.88 | $27.4M | -- | $0.00 | 0% | -- |
|
INSM
Insmed
|
$69.18 | $95.78 | $12.5B | -- | $0.00 | 0% | 31.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
-- | 1.659 | -- | 3.54x |
|
ACAD
ACADIA Pharmaceuticals
|
-- | 0.878 | -- | 2.18x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
AXSM
Axsome Therapeutics
|
76.02% | 1.663 | 4.39% | 1.99x |
|
GRCE
Grace Therapeutics
|
-- | 1.718 | -- | -- |
|
INSM
Insmed
|
79.45% | 5.493 | 8.91% | 4.99x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$56M | -$81.3M | -46.69% | -46.69% | -132.16% | -$35.6M |
|
ACAD
ACADIA Pharmaceuticals
|
$237.8M | $7M | 41.59% | 41.59% | 2.69% | $39.9M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
AXSM
Axsome Therapeutics
|
$108.3M | -$61.6M | -96.73% | -244.32% | -61.14% | -$26.2M |
|
GRCE
Grace Therapeutics
|
-- | -$3.7M | -- | -- | -- | -$4.1M |
|
INSM
Insmed
|
$78.3M | -$245.2M | -82.19% | -41989.34% | -205.36% | -$202.8M |
SpringWorks Therapeutics vs. Competitors
-
Which has Higher Returns SWTX or ACAD?
ACADIA Pharmaceuticals has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 55.37%. SpringWorks Therapeutics's return on equity of -46.69% beat ACADIA Pharmaceuticals's return on equity of 41.59%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M -
What do Analysts Say About SWTX or ACAD?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 86.43%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $24.85 which suggests that it could grow by 61.57%. Given that SpringWorks Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 ACADACADIA Pharmaceuticals6 7 0 -
Is SWTX or ACAD More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.313%.
-
Which is a Better Dividend Stock SWTX or ACAD?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or ACAD?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $259.6M. SpringWorks Therapeutics's net income of -$77.3M is lower than ACADIA Pharmaceuticals's net income of $143.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 11.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.13x versus 2.67x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M
-
Which has Higher Returns SWTX or ADMA?
ADMA Biologics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 95.19%. SpringWorks Therapeutics's return on equity of -46.69% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About SWTX or ADMA?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 86.43%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 40.33%. Given that SpringWorks Therapeutics has higher upside potential than ADMA Biologics, analysts believe SpringWorks Therapeutics is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 ADMAADMA Biologics4 0 0 -
Is SWTX or ADMA More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock SWTX or ADMA?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or ADMA?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. SpringWorks Therapeutics's net income of -$77.3M is lower than ADMA Biologics's net income of $111.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 21.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.13x versus 10.26x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M ADMAADMA Biologics10.26x 21.96x $117.5M $111.9M
-
Which has Higher Returns SWTX or AXSM?
Axsome Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -63.08%. SpringWorks Therapeutics's return on equity of -46.69% beat Axsome Therapeutics's return on equity of -244.32%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M AXSMAxsome Therapeutics91.15% -$1.54 $237.7M -
What do Analysts Say About SWTX or AXSM?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 86.43%. On the other hand Axsome Therapeutics has an analysts' consensus of $173.89 which suggests that it could grow by 74.34%. Given that SpringWorks Therapeutics has higher upside potential than Axsome Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Axsome Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 AXSMAxsome Therapeutics13 0 0 -
Is SWTX or AXSM More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.73%.
-
Which is a Better Dividend Stock SWTX or AXSM?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or AXSM?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. SpringWorks Therapeutics's net income of -$77.3M is lower than Axsome Therapeutics's net income of -$74.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.13x versus 12.28x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M AXSMAxsome Therapeutics12.28x -- $118.8M -$74.9M
-
Which has Higher Returns SWTX or GRCE?
Grace Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -46.69% beat Grace Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M GRCEGrace Therapeutics-- -$0.36 -- -
What do Analysts Say About SWTX or GRCE?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 86.43%. On the other hand Grace Therapeutics has an analysts' consensus of $11.88 which suggests that it could grow by 493.9%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 GRCEGrace Therapeutics1 0 0 -
Is SWTX or GRCE More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.327, suggesting its more volatile than the S&P 500 by 32.655%.
-
Which is a Better Dividend Stock SWTX or GRCE?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or GRCE?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Grace Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$77.3M is lower than Grace Therapeutics's net income of -$4.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.13x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M GRCEGrace Therapeutics-- -- -- -$4.2M
-
Which has Higher Returns SWTX or INSM?
Insmed has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -225.53%. SpringWorks Therapeutics's return on equity of -46.69% beat Insmed's return on equity of -41989.34%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M INSMInsmed74.96% -$1.32 $1.4B -
What do Analysts Say About SWTX or INSM?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 86.43%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 38.45%. Given that SpringWorks Therapeutics has higher upside potential than Insmed, analysts believe SpringWorks Therapeutics is more attractive than Insmed.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 INSMInsmed12 0 0 -
Is SWTX or INSM More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.
-
Which is a Better Dividend Stock SWTX or INSM?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or INSM?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Insmed quarterly revenues of $104.4M. SpringWorks Therapeutics's net income of -$77.3M is higher than Insmed's net income of -$235.5M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 15.13x versus 31.19x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M INSMInsmed31.19x -- $104.4M -$235.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Sweetgreen Stock Worth Holding For the Next Five Years?
Sweetgreen (NYSE:SG) is an up-and-coming quick service restaurant chain focused…
What Do I Need to Know About Alcoa Stock?
Alcoa (AA) is a global leader in aluminum production. Based…
Stock Ideas
Sell
37
Is AAPL Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
31
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 32x
Alerts
Sell
25
GDXU alert for Apr 7
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 1.93% over the past day.
Buy
76
SOXS alert for Apr 7
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is down 7.07% over the past day.
Sell
15
FAS alert for Apr 7
Direxion Daily Financial Bull 3x Shares [FAS] is down 0.96% over the past day.
